Abstract |
Fotemustine is a third-generation nitrosourea characterized by a phosphoalanine carrier group grafted onto the nitrosourea radical, which gives it a high lipophilicity and a better penetration through the cell membrane. Between September 1988 and December 1997, 22 patients with inoperable or incompletely resected recurrent high-grade gliomas of the brain were treated at the University Hospital in Brest (France). Treatment consisted of three weekly infusions of fotemustine (100 mg/m2 days 1, 8 and 15). If patients responded or were stabilized, fotemustine was continued at the same dose, but every three weeks only. Four patients responded to the treatment (18%), while 6 were stabilized (32%). Main toxicity was haematologic (leucopenia and, above all, thrombocytopenia); treatment was only interrupted in one patient for leucothrombopenia, and there was no toxic death. Medium duration of response and/or stabilisation was 6.5 months, and median survival 9.4 months in responding and/or stabilized patients, while it was only 5.0 months if tumour progressed under chemotherapy (median survival for all patients: 7.5 months). Besides, there was a difference in survival in favour of the young patients (< 50 years-median survival = 11.8 months) in comparison with patients between 50 and 60 years (median survival = 6.8 months; p = 0.0282) or elderly patients (> 60 years-median survival = 5.8 months; p = 0.0634). In our series, we did not found any difference in survival according to the initial performance status of patients before treatment. Therefore, fotemustine seems to represent an interesting well-tolerated treatment possibility in patients with inoperable recurrent malignant gliomas of the brain.
|
Authors | J P Malhaire, B Lucas, H Simon, H Person, P Dam-Hieu, J P Labat |
Journal | Bulletin du cancer
(Bull Cancer)
Vol. 86
Issue 3
Pg. 289-94
(Mar 1999)
ISSN: 0007-4551 [Print] France |
Vernacular Title | Fotémustine (Muphoran) chez 22 patients présentant des récidives de gliomes cérébraux de haut grade. |
PMID | 10210763
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Nitrosourea Compounds
- Organophosphorus Compounds
- fotemustine
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Astrocytoma
(drug therapy, mortality, pathology)
- Brain Neoplasms
(drug therapy, mortality, pathology)
- Female
- Glioblastoma
(drug therapy, mortality, pathology)
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, mortality, pathology)
- Nitrosourea Compounds
(therapeutic use)
- Organophosphorus Compounds
(therapeutic use)
|